Pharmacokinetic and pharmacodynamic analysis of Moxifloxacin Hydrochloride and Sodium Chloride Injection in the treatment of lower respiratory tract infection
ZHANG Chao1 XIAO Ting2▲
1. Clinical Pharmacy, Jiujiang First People′s Hospital, Jiangxi Province, Jiujiang 332000, China;
2. Department of Geriatrics, Jiujiang First People′s Hospital, Jiangxi Province, Jiujiang 332000, China
Abstract：Objective To analyze the pharmacokinetics and pharmacodynamics of Moxifloxacin Hydrochloride and Sodium Chloride Injection in patients with lower respiratory tract infection (LRTI). Methods Seventy-six LRTI patients admitted to Jiujiang First People′s Hospital from March 2019 to March 2021 were selected as the study subjects. All patients received intravenous infusion of moxifloxacin hydrochloride and sodium chloride injection. Blood concentration of moxifloxacin (Mox) was determined by high performance liquid chromatography, and minimum inhibitory concentration (MIC) of bacteria was determined by broth dilution method. The therapeutic effect, etiological efficacy, plasma concentration of Mox and MIC of pathogenic bacteria were observed. Results The total effective rate of 76 patients was 89.47% (68/76), among which the total effective rate of 36 patients with pneumonia was up to 100.00% (36/36). Before treatment, 76 strains of pathogenic bacteria were detected in 76 patients, among which Mycoplasma pneumoniae had the highest detection rate, followed by Staphylococcus aureus. The clearance rate of pathogenic bacteria after treatment was 90.79% (69/76). After single dose, Mox peak concentration, trough concentration and steady-state plasma concentration were (4.25±0.06) mg/L, (1.44±0.08) mg/L and (3.67±0.05) mg/L, respectively. Mox showed good sensitivity to Mycoplasma pneumoniae and Streptococcus pneumoniae, with MIC of 0.25 mg/L. Mox had poor sensitivity to Staphylococcus aureus. Conclusion Moxifloxacin hydrochloride and sodium chloride injection has a better therapeutic effect in LRTI patients, which can achieve effective therapeutic concentration and remove pathogenic bacteria.
京公网安备 11010502046607号